Herbal Compound Coptisine Stabilizes SIRT1 to Reverse Polycystic Ovary Syndrome
A traditional Chinese herbal formula and its active compound coptisine correct PCOS by protecting SIRT1 protein from degradation and normalizing ovarian hormone production.
Summary
Researchers at Tongji Hospital investigated how the traditional Chinese herbal formula Jiao-tai-wan (JTW) and its active compound coptisine treat polycystic ovary syndrome (PCOS). Using a rat model and cell studies, they found that coptisine works by preventing the breakdown of SIRT1, a key protein involved in metabolism and cellular health. By stabilizing SIRT1, coptisine corrects abnormal mitochondrial function in ovarian cells, reduces excess cholesterol transport into mitochondria, and normalizes the overproduction of androgens that drives PCOS symptoms. The compound directly binds SIRT1 with high affinity and blocks an enzyme (SMURF2) that would otherwise tag SIRT1 for destruction. These findings identify coptisine as a natural SIRT1 stabilizer and offer a mechanistic explanation for JTW's traditional clinical use in hormonal disorders.
Detailed Summary
Polycystic ovary syndrome affects roughly 10% of reproductive-age women worldwide, causing hormonal imbalance, irregular ovulation, insulin resistance, and metabolic dysfunction. Despite its prevalence, treatment options remain limited, making the search for new mechanistic targets important. This study investigates how the traditional Chinese herbal formula Jiao-tai-wan (JTW) and its isolated alkaloid component coptisine exert therapeutic effects in PCOS.
Researchers established a PCOS rat model using DHEA injections and treated animals with low-dose JTW, high-dose JTW, metformin, or coptisine alone. In parallel, primary ovarian theca cells were used for mechanistic in vitro work. RNA sequencing, network pharmacology, co-immunoprecipitation, and biophysical binding assays were employed to map the molecular pathway.
JTW treatment improved ovulation, corrected sex hormone imbalances, reduced glycolipid metabolic disturbances, and lowered oxidative stress in PCOS rats. RNA sequencing pointed to the steroidogenesis pathway as a key target. Mechanistically, JTW and coptisine restored normal mitochondrial dynamics in theca cells and reduced the localization of StAR — the protein that shuttles cholesterol into mitochondria for androgen synthesis — to the outer mitochondrial membrane. SIRT1 emerged as the central mediator: coptisine did not increase SIRT1 gene transcription but instead prevented SIRT1 protein degradation by blocking the E3 ubiquitin ligase SMURF2 from tagging SIRT1 for destruction. Biophysical assays confirmed direct coptisine-SIRT1 binding at a KD of 5.71 μM.
These findings are significant because SIRT1 is a well-established longevity-associated protein involved in mitochondrial biogenesis, inflammation, and metabolic regulation. Identifying a natural small molecule that stabilizes SIRT1 post-translationally opens a new avenue for both PCOS treatment and broader metabolic health applications.
Caveats include the preclinical nature of the work, reliance on a DHEA-induced rat model that imperfectly mirrors human PCOS, and the absence of human clinical data. The summary is based on the abstract only.
Key Findings
- Coptisine stabilizes SIRT1 protein by blocking SMURF2-mediated ubiquitination, without altering SIRT1 gene expression.
- Coptisine directly binds SIRT1 with high affinity (KD = 5.71 μM), acting as a natural protein stabilizer.
- JTW and coptisine reduce mitochondrial cholesterol import by limiting StAR localization to the outer mitochondrial membrane.
- Treatment corrected androgen excess, restored ovulation, and improved insulin and lipid metabolism in PCOS rats.
- Effects of coptisine mirrored SIRT1 overexpression and were blocked by SIRT1 knockdown, confirming on-target action.
Methodology
PCOS was induced in rats via DHEA injection; treatment groups included JTW (two doses), metformin, and coptisine. Mechanistic studies used primary theca cells with RNA sequencing, network pharmacology, co-immunoprecipitation, CETSA, SPR binding assays, confocal imaging, and transmission electron microscopy to map the SIRT1-SMURF2-StAR pathway.
Study Limitations
The study relies on a DHEA-induced rat model, which does not fully replicate the heterogeneous pathophysiology of human PCOS. No human clinical data are presented, limiting direct translational conclusions. This summary is based on the abstract only, so full methodological details and supplementary data could not be assessed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.